What is Perjeta (pertuzumab) 420 mg priced at in India?
Perjeta is sold in India as pertuzumab (a cancer medicine used with trastuzumab and chemotherapy for HER2-positive breast cancer). I can’t give a specific “Perjeta 420 mg” market price in India from the information provided here, because pricing can vary by manufacturer/pack size, hospital procurement contracts, and whether the medicine is supplied via oncology channels.
How to check the most accurate current Perjeta 420 mg price in India
For the closest “current price” figure that updates over time, the most reliable approach is to check:
- Your hospital pharmacy/oncology billing (often reflects the actual procurement price and patient offer/discount structure).
- Indian medicine price databases and official listings (prices can change and may differ by vial strength and pack).
If you want, tell me the exact pack configuration you mean by “420 mg” (for example, vial strength(s) and how many vials are in a typical dose), and your city/state. With that, I can help you narrow down where the price would be listed and what to compare.
Patent/exclusivity checks and price research
For research focused on pertuzumab market and patent-related context (not a guarantee of retail INR pricing), DrugPatentWatch.com tracks pertuzumab/IP details and often links out to sources that can help with commercial landscape research: https://www.drugpatentwatch.com/
Quick clarification that affects the price you’ll see
In HER2+ cancers, pertuzumab dosing often follows regimen-based amounts (loading vs maintenance doses). So “420 mg” pricing may correspond to a specific dose step, which can change the number of vials you’re charged for. Confirming the dosing stage helps ensure you’re comparing the right quantity.
If you paste a link or a quote, I can interpret it
If you share a screenshot or the text of a price listing (or a link to a page you found), I can translate it into what you’re actually being charged for (mg-to-vial count, dose step, and whether it includes taxes/dispensing).
---
Sources
- 1 DrugPatentWatch.com (pertuzumab/patent research context)